Your browser doesn't support javascript.
Hemagglutinin-esterase cannot be considered as a candidate for designing drug against COVID-19.
Zandi, Milad; Soltani, Saber.
  • Zandi M; Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Miladzandi416@gmail.com.
  • Soltani S; Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran. Miladzandi416@gmail.com.
Mol Divers ; 25(3): 1999-2000, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1303350
ABSTRACT
We read with interest the article by Patel et al. on the identification of potential inhibitors of coronavirus hemagglutinin-esterase. The authors considered hemagglutinin-esterase as a glycoprotein of SARS-CoV-2 and selected hemagglutinin-esterase as a target to identify potential inhibitors using a combination of various computational approaches, and however, SARS-CoV-2 genome lacks hemagglutinin-esterase gene; thus, hemagglutinin-esterase does not exist in SARS-CoV-2 particle.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Drug Design / Molecular Targeted Therapy / COVID-19 Drug Treatment Language: English Journal: Mol Divers Journal subject: Molecular Biology Year: 2021 Document Type: Article Affiliation country: S11030-021-10272-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Drug Design / Molecular Targeted Therapy / COVID-19 Drug Treatment Language: English Journal: Mol Divers Journal subject: Molecular Biology Year: 2021 Document Type: Article Affiliation country: S11030-021-10272-w